Stevens - Johnson Syndrome and Toxic Epidermal Necrolysis; Extensive Review of Reports of Drug-Induced Etiologies, and Possible Therapeutic Modalities
DOI:
https://doi.org/10.3889/oamjms.2018.148Keywords:
Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis, Drug hypersensitivity, Adverse drug reaction, skin, mucous membranesAbstract
Stevens - Johnson Syndrome and Toxic Epidermal Necrolysis are adverse hypersensitivity reactions that affect the skin and mucous membranes. They are characterised by erythematous macules and hemorrhagic erosions of the mucous membranes. Epidermal detachments of varying degrees of severity also occur in these conditions. Various aetiologies are associated with these conditions, with adverse drug reaction being the most common. Though the worldwide incidence of these conditions is recorded as low, diverse types of medication are being observed to lead to these conditions. This review compiles information on the details of Stevens-Johnson syndrome and Toxic Epidermal Necrolysis, the pathophysiology, therapeutic management, and largely considers the drug-induced etiologies associated with these conditions.
Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Mockenhaupt M. The current understanding of Stevens-Johnson syndrome and toxic epidermal necrolysis. Expert Rev Clin Immunol. 2011; 7: 803-813. https://doi.org/10.1586/eci.11.66 PMid:22014021
Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome and erythema multiforme. Arch Dermatol. 1993; 129: 92-96. https://doi.org/10.1001/archderm.1993.01680220104023
Chung WH, Hung SI, Hong HS, Hsih MS, Yang LC, Ho HC, Wu JY, Chen YT. Medical genetics: a marker for Stevens-Johnson syndrome. Nature. 2004; 428:486. https://doi.org/10.1038/428486a PMid:15057820
Downey A, Jackson C, Harun N, Cooper A. Toxic epidermal necrolysis: Review of pathogenesis and management. Journal of the American Academy of Dermatology. 2012; 66(6):995-1003. https://doi.org/10.1016/j.jaad.2011.09.029 PMid:22169256
Schwartz R, McDonough P, Lee B. Toxic epidermal necrolysis. Journal of the American Academy of Dermatology. 2013; 69(2):187.e1-187.e16. https://doi.org/10.1016/j.jaad.2013.05.002 PMid:23866879
Man CB, Kwan P, Baum L, Yu E, Lau KM, Cheng AS, Ng MH. Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia. 2007; 48:1015–1018. https://doi.org/10.1111/j.1528-1167.2007.01022.x PMid:17509004
Tassaneeyakul W, Tiamkao S, Jantararoungtong T, Chen P, Lin SY, Chen WH, Konyoung P, Khunarkornsiri U, Auvichayapat N, Pavakul K. et al. Association between HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population. Epilepsia. 2010; 51:926–930. https://doi.org/10.1111/j.1528-1167.2010.02533.x PMid:20345939
Alfirevic A, Jorgensen AL, Williamson PR, Chadwick DW, Park BK, Pirmohamed M. HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. Pharmacogenomics. 2006; 7:813–818. https://doi.org/10.2217/14622416.7.6.813 PMid:16981842
Kaniwa N, Saito Y, Aihara M, Matsunaga K, Tohkin M, Kurose K, Sawada J, Furuya H, Takahashi Y, Muramatsu M. et al. HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics. 2008; 9:1617–1622. https://doi.org/10.2217/14622416.9.11.1617 PMid:19018717
Lonjou C, Thomas L, Borot N, Ledger N, de Toma C, LeLouet H, Graf E, Schumacher M, Hovnanian A, Mockenhaupt M, Roujeau JC. A marker for Stevens-Johnson syndrome: ethnicity matters. Pharmacogenomics J. 2006; 6:265–268. https://doi.org/10.1038/sj.tpj.6500356 PMid:16415921
Lonjou C, Borot N, Sekula P, Ledger N, Thomas L, Halevy S, Naldi L, Bouwes-Bavinck JN, Sidoroff A, de Toma C. et al. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics. 2008; 18:99–107. https://doi.org/10.1097/FPC.0b013e3282f3ef9c PMid:18192896
Hung SI, Chung WH, Liou LB, Chu CC, Lin M, Huang HP, Lin YL, Lan JL, Yang LC, Hong HS. et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA. 2005; 102:4134–4139. https://doi.org/10.1073/pnas.0409500102 PMid:15743917 PMCid:PMC554812
Lebargy F, Wolkenstein P, Gisselbrecht M, Lange F, Fleury-Feith J, Delclaux C, Roupie E, Revuz J, Roujeau JC: Pulmonary complications in toxic epidermal necrolysis: a prospective clinical study. Intensive Care Med. 1997; 23: 1237-1244. https://doi.org/10.1007/s001340050492
Revuz J, Penso D, Roujeau JC, Guillaume JC, Payne CR, Wechsler J, Touraine R: Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients. Arch Dermatol. 1987; 123: 1160-1165. https://doi.org/10.1001/archderm.1987.01660330071012 PMid:3632000
Chang YS, Huang FC, Tseng SH, Hsu CK, Ho CL, Sheu HM: Erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis: acute ocular manifestations, causes, and management. Cornea. 2007; 26: 123-129. https://doi.org/10.1097/ICO.0b013e31802eb264 PMid:17251797
Sotozono C, Ueta M, Koizumi N, Inatomi T, Shirakata Y, Ikezawa Z, Hashimoto K, Kinoshita S: Diagnosis and treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis with ocular complications. Ophthalmology. 2009; 116: 685-690. https://doi.org/10.1016/j.ophtha.2008.12.048 PMid:19243825
Yip LW, Thong BY, Lim J, Tan AW, Wong HB, Handa S, Heng WJ: Ocular manifestations and complications of Stevens-Johnson syndrome and toxic epidermal necrolysis: an Asian series. Allergy. 2007; 62: 527-531. https://doi.org/10.1111/j.1398-9995.2006.01295.x PMid:17313402
Magina S, Lisboa C, Leal V, Palmares J, Mesquita-Guimaraes J: Dermatological and ophthalmological sequels in toxic epidermal necrolysis. Dermatology. 2003; 207: 33-36. https://doi.org/10.1159/000070938 PMid:12835545
Sheridan RL, Schulz JT, Ryan CM, Schnitzer JJ, Lawlor D, Driscoll DN, Donelan MB, Tompkins RG: Long-term consequences of toxic epidermal necrolysis in children. Pediatrics. 2002; 109: 74-78. https://doi.org/10.1542/peds.109.1.74
Oplatek A, Brown K, Sen S, Halerz M, Supple K, Gamelli RL: Long-term follow-up of patients treated for toxic epidermal necrolysis. J Burn Care Res. 2006; 27: 26-33. https://doi.org/10.1097/01.bcr.0000194268.01514.f8 PMid:16566534
Roujeau JC, Guillaume JC, Revuz J, Touraine R: Reporting adverse drug reactions. Lancet. 1985: 2: 1244-10. https://doi.org/10.1016/S0140-6736(85)90771-8
Saban J, Pais JR, Rodriguez JL, Boixeda D: Sjogren-like pluriglandular exocrine insufficiency after drug-induced toxic epidermal necrolysis. Postgrad Med J. 1991; 67: 195-197. https://doi.org/10.1136/pgmj.67.784.195
Mockenhaupt M, Viboud C, Dunant A, Naldi L, Halevy S,Bouwes Bavinck JN, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication riskswith emphasis on recently marketed drugs. The EuroSCAR study. J Invest Dermatol 2008; 128:35-44. https://doi.org/10.1038/sj.jid.5701033 PMid:17805350
Rojeau JC, Kelly JP et al: Medication use and the risk of Steven Johnson syndrome or toxic epidermal necrolysis. The New England Journal of Medicine, 1995; 333:1600-1608. https://doi.org/10.1056/NEJM199512143332404 PMid:7477195
Ling YF, Yang CH et al .Severe cutaneous adverse reactions related to systemic antibiotics. Clinical Infectious Diseases. 2014; 58(10):1377–1385. https://doi.org/10.1093/cid/ciu126 PMid:24599767
Fatallah N et al. Co-amoxiclav-induced Stevens Johnson Syndrome in a child. Pan African Medical Journal. 2013; 14:38.
https://doi.org/10.11604/pamj.2013.14.38.1408
Hallgren J et al. Stevens-Johnson associated with ciprofloxacin: A review of adverse cutaneous events reported in Sweden associated with this drug. J Am Acad Dermatol. 2003; 49:s267-9. https://doi.org/10.1016/S0190-9622(03)00478-X
Maciejewska et al. Stevens-Johnson syndrome/toxic epidermal necrolysis presumably induced by norfloxacin. Postep Derm Alergol. 2014; 31, 3:194–196. https://doi.org/10.5114/pdia.2014.40796 PMid:25097494 PMCid:PMC4112256
Lau B ,Mutyala D,Dhaliwal D.A Case report of Doxycycline induced Steven Johnson syndrome. Corneal Journal. 2011; 30: 595-597. https://doi.org/10.1097/ICO.0b013e3181f05773 PMid:21099409
Yoon J, Lee SH et al: Concurrence of stevens johnson syndrome and bilateral parotitis after minocycline therapy. Case rep dermatol. 2010; 2:88-94. https://doi.org/10.1159/000314952
PMid:21103193 PMCid:PMC2988842
Nappe TM. Steven Johnson syndrome after treatment with azithromycin. An uncommon culprit. American journal of emergency medicine. 2016; 34:676e1-676e3.
Liberopoulos E et al. Possible Cefotaxime-Induced Stevens–Johnson Syndrome. The Annals of Pharmacotherapy. 2003; 37:812-814. https://doi.org/10.1345/aph.1C453 PMid:12773067
Luciano M, et al. Stevens-Johnson syndrome caused by cefepime; Journal of Pharmacology and Pharmacotherapeutics. 2015; 2015:35.
Mazumdar, Goutameswar, and Koushik Shome. Stevens-Johnson syndrome following use of metronidazole in a dental patient. Indian Journal of Pharmacology. 2014; 46(1):121. https://doi.org/10.4103/0253-7613.125193 PMid:24550598 PMCid:PMC3912796
Hun YF, Wu XT, et al. Phenytoin-induced Stevens–Johnson syndrome with negative HLA-B*1502 allele in mainland China: Two cases. Elsevier seizure. 2011; 20:431-432. https://doi.org/10.1016/j.seizure.2011.01.005 PMid:21334226
Hilas O, Charneski L. Lamotrigine induced steven johnson syndrome. Am J Health Syst Pharm. 2007; 64:273-275. https://doi.org/10.2146/ajhp060071 PMid:17244876
Devi, K., et al. The commonest cause of toxic epidermal necrolysis and Stevens-Johnson syndrome: A study of 7 years. Indian Journal of Dermatology, Venereology and Leprology. 2005; 71(5):325. https://doi.org/10.4103/0378-6323.16782
Sharma SR, Sharma N, Yeolekar ME. Oxcarbazepine-induced Stevens Johnson syndrome: A rare case report. Indian Dermatol Online J. 2011; 2:13-5. https://doi.org/10.4103/2229-5178.79861 PMid:23130207 PMCid:PMC3481788
Gaur, Sumit, and Rupali Agnihotri. Phenobarbital induced Stevens-Johnson syndrome in a child. Indian Journal of Pharmacology. 2012; 44(4):531. https://doi.org/10.4103/0253-7613.99344 PMid:23087523 PMCid:PMC3469965
Naveen, K, et al. Stevens-Johnson syndrome induced by sodium valproate monotherapy. International Journal of Critical Illness and Injury Science. 2012; 2(1):44. https://doi.org/10.4103/2229-5151.94904 PMid:22624102 PMCid:PMC3354377
Zou LP, Ding CH, et al. Stevens Johnson syndrome induced by levetiracetam. Elsevier Seizure. 2012; 21:823-825. https://doi.org/10.1016/j.seizure.2012.09.005 PMid:23036769
Cheng JB,Anderson RC et al.Stevens Johnson Syndrome associated with Glipizide Therapy. Dermatitis. 2006; 17(1):36-38. https://doi.org/10.2310/6620.2006.05038
Wright AA, Vesta K, et al. Stevens-Johnson Syndrome Associated With Furosemide: A Case Report. Journal of Pharmacy practice. 2010; 23(4):367-370. https://doi.org/10.1177/0897190010362260 PMid:21507837
Her Y et al. Stevens–Johnson syndrome induced by acetazolamide. Journal of Dermatology. 2011; 38: 272–275. https://doi.org/10.1111/j.1346-8138.2010.00921.x PMid:21342230
Babamahmoodi F, Eslami G, et al. Diclofenac-Induced Stevens-Johnson Syndrome: A Case Report . Iranian journal of pharmacology & therapeutics. 2012; 11: 33-35.
Angadi S, Karn A. Ibuprofen induced Stevens-Johnson syndrome-toxic epidermal necrolysis in Nepal. Asia Pac Allergy. 2016; 6:70-73. https://doi.org/10.5415/apallergy.2016.6.1.70 PMid:26844223 PMCid:PMC4731484
Goldberg D, Panigrahi D, et al. A Case of Rofecoxib-Associated Stevens-Johnson syndrome With Corneal and Conjunctival Changes. Cornea. 2004; 23(7):736-737. https://doi.org/10.1097/01.ico.0000126330.77228.a3 PMid:15448505
Biswal S, Sourav S. Paracetamol induced Stevens-Johnson syndrome – toxic epidermal necrolysis overlap syndrome. International journal of Dermatology. 2014; 53:1042–1044. https://doi.org/10.1111/ijd.12355 PMid:24673330
Bhasin A, et al. First case of mirtazepine-induced Stevens-Johnson syndrome from India; Indian Journal of Pharmacology. 2012; 44(5):656. https://doi.org/10.4103/0253-7613.100411 PMid:23112435 PMCid:PMC3480806
Strawn J, Whitsel R, et al. Atypical stevens Johnson syndrome in an adolescenttreated with duloxetine. Journal of child and adolescent psychopharmacology. 2011; 21:91-92. https://doi.org/10.1089/cap.2010.0071 PMid:21309700
Doesch J, Debus D et al. Afatinib-associated Stevens-Johnson syndrome in an EGFR-mutated lung cancer patient. Elsevier. Lung Cancer. 2016; 95:35–38. https://doi.org/10.1016/j.lungcan.2016.02.015 PMid:27040849
Yoon J, et al. Stevens-Johnson Syndrome Induced by Vandetanib. Ann Dermatol. 2011; 23(Suppl. 3): S343-5. https://doi.org/10.5021/ad.2011.23.S3.S343 PMid:22346274 PMCid:PMC3276793
Jha P, Himanshu D, Jain N, Singh AK. Imatinib-induced Stevens-Johnsons syndrome. BMJ case reports. 2013; 2013:bcr2012007926.
Lee J et al. Case of sunitinib-induced Stevens–Johnson syndrome.Journal of dermatology. 2013; 40(9):753-4. https://doi.org/10.1111/1346-8138.12219 PMid:23855706
Mockenhaupt M. Allopurinol is the most frequent cause of Stevens-Johnson syndrome and toxic epidermal necrolysis. Expert Review of Dermatology. 2012; 7(3):213. https://doi.org/10.1586/edm.12.5
Koh WL, Tay YK, Koh MJA. Danazol-induced Stevens-Johnson syndrome in a patient with systemic lupus erythematosus. Dermatology Online Journal. 2015; 21(1):17.
Cocoa S, Viviano M. Stevens-Johnson syndrome and abuse of anabolic steroids. J Korean Assoc Oral Maxillofac Surg. 2017; 43:57-60. https://doi.org/10.5125/jkaoms.2017.43.1.57 PMid:28280713 PMCid:PMC5342976
Hiraki et al. Stevens-Johnson Syndrome Induced by Paclitaxel in a Patient with Squamous Cell Carcinoma of the Lung. Anticancer research. 2004; 24:1135-1138. PMid:15154637
Sawada Y. Docetaxel-induced StevensJohnson syndrome with regenerating epidermis composed of atypical keratinocytes. European Academy of Dermatology and Venereology. 2009; 23:1333-1334. https://doi.org/10.1111/j.1468-3083.2009.03183.x PMid:19453796
Minakawa S, et al. Tegafur/gimeracil/oteracil (TS-1) induced StevenseJohnson syndrome. Dermatologica Sinica. 2013; 31:154e156.
Smith EV, Pynn MC, Blackford S, Leopold DJ. Stevens–Johnson syndrome secondary to oseltamivir (Tamiflu®). Br J Gen Pract. 2010; 60(571):133-4. https://doi.org/10.3399/bjgp10X483292 PMid:20132714 PMCid:PMC2814276
Chattopadhyay P, Sarma N. Adefovir-induced Stevens-Johnson syndrome and toxic epidermal necrolysis overlap syndrome. Singapore Med J. 2011; 52(2):31-34.
Singh H, et al. Nevirapine induced Stevens-Johnson syndrome in an HIV infected patient. Indian Journal of Pharmacology. 2011; 43(1):84. https://doi.org/10.4103/0253-7613.75680 PMid:21455432 PMCid:PMC3062132
Jao T, et al. Aggrenox (Asasantin retard)-induced Stevens–Johnson syndrome. British Journal of Clinical Pharmacology. 2008; 67(2):264-265. https://doi.org/10.1111/j.1365-2125.2008.03340.x PMid:19094159 PMCid:PMC2670386
Das A et al. Johnson syndrome with toxic epidermal necrolysis due to thalidomide in a case of multiple myeloma. Indian Journal of Pharmacology. 2014; 46(5):557. https://doi.org/10.4103/0253-7613.140598 PMid:25298592 PMCid:PMC4175899
Allegra A, Alonci A, et al. Stevens–Johnson syndrome after lenalidomide therapy for multiple myeloma: a case report and a review of treatment options. Hematol Oncol. 2012; 30:41–45. https://doi.org/10.1002/hon.1000 PMid:21702057
Kakushi M, Atsuo O, et al. Stevens–Johnson syndrome induced by mizoribine in a patient with systemic lupus erythematosus, Modern Rheumatology. 2006; 16(2):113-116. https://doi.org/10.3109/s10165-006-0467-5
Teo SL, Santosa A. Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Overlap Induced by Fexofenadine. J Investig Allergol Clin Immunol. 2017; 27(3):191-193. https://doi.org/10.18176/jiaci.0158 PMid:28570227
Oskay T. Stevens–Johnson Syndrome associated with Ramipril. International Journal of Dermatology 2003; 42:580–58. https://doi.org/10.1046/j.1365-4362.2003.01838.x PMid:12839617
Tan KW, Wang YS, Tay YK. Stevens-Johnson Syndrome Due to Strontium Ranelate. Annals Academy of Medicine. 2011; 40:11.
Lafitte E, et al. Severe Stevens–Johnson syndrome induced by contrast medium iopentol. British Journal of Dermatology. 2004; 150: 376–377. https://doi.org/10.1111/j.1365-2133.2003.05763.x
Lim JH, et al. Stevens–Johnson syndrome following occupational exposure to carbamate insecticide. Journal of Dermatology. 2010; 37:182–184. https://doi.org/10.1111/j.1346-8138.2009.00784.x PMid:20175856
Rajendran N, Chitfambalam PC, Jayaraman AM. Carbamate pesticide induced toxic epidermal necrolysis.Indian J Dermatol Venereol Leprol. 2001; 67:253–254. PMid:17664764
Zaidi M, et al. Amoxycillin and Clavulanic Acid Induced Stevens-Johnson Syndrome: A Case Report. Excli Journal. 2017; 16:748–751. PMid:28827990 PMCid:PMC5547378
Biswal S, Sahoo SS. Paracetamol induced Stevensâ€Johnson syndrome–toxic epidermal necrolysis overlap syndrome. International journal of dermatology. 2014; 53(8):1042-4. https://doi.org/10.1111/ijd.12355 PMid:24673330
Bajwa SJ, Kaur J. Stevens–Johnsons syndrome and toxic epidermal necrolysis: Need to look beyond current etiologies, diagnostics, and therapeutics. Medical Journal of Dr. DY Patil Vidyapeeth. 2017; 10(1):68. https://doi.org/10.4103/0975-2870.197913
Kohanim S, Palioura S, Saeed HN, Akpek EK, Amescua G, Basu S, Blomquist PH, Bouchard CS, Dart JK, Gai X, Gomes JA. Stevens-Johnson syndrome/toxic epidermal necrolysis–a comprehensive review and guide to therapy. I. Systemic disease. The ocular surface. 2016; 14(1):2-19. https://doi.org/10.1016/j.jtos.2015.10.002 PMid:26549248
Schneider J, Cohen P. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Concise Review with a Comprehensive Summary of Therapeutic Interventions Emphasizing Supportive Measures. Advances in Therapy. 2017; 34(6):1235-1244. https://doi.org/10.1007/s12325-017-0530-y PMid:28439852 PMCid:PMC5487863
Maciejewska J, et al. Stevens-Johnson syndrome/Toxic epidermal necrolysis presumably induced by norfloxacin. Advances in Dermatology and Allergology. 2014; 3:194–196. https://doi.org/10.5114/pdia.2014.40796 PMid:25097494 PMCid:PMC4112256
Allegra, A, et al. Stevens-Johnson syndrome after lenalidomide therapy for multiple myeloma: a case report and a review of treatment options. Hematological Oncology. 2011; 30(1):41–45. https://doi.org/10.1002/hon.1000 PMid:21702057
Downloads
Published
How to Cite
Issue
Section
License
http://creativecommons.org/licenses/by-nc/4.0
